Koi Peptides has introduced a certificate-of-analysis (COA)-verified formulation of BPC-157 — Body Protection Compound 157 — positioned strictly as a research-use-only reference compound for laboratory applications. The material is characterized by both high-performance liquid chromatography (HPLC) and mass spectrometry (MS), offering researchers an identity- and purity-confirmed starting point for preclinical investigation.
BPC-157 is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. In preclinical rodent models, it has been studied for its apparent role in promoting angiogenesis, modulating nitric oxide synthesis, and accelerating soft-tissue and tendon repair — though no double-blind, placebo-controlled human clinical trials have yet established efficacy endpoints sufficient to support a structure-function claim under current FDA guidelines. The compound does not hold GRAS status, and no NDI (New Dietary Ingredient) notification has been accepted for BPC-157 in finished formulations sold to consumers, a regulatory gap that has drawn increased agency attention in recent years.
The significance of Koi Peptides' positioning lies in that explicit research-use-only designation. By supplying the compound as a characterized reference material — complete with COA documentation, HPLC purity data, and MS confirmation — the company distances itself from the grey-market finished-supplement channel, where BPC-157 has circulated in oral capsule and injectable formats despite unresolved regulatory status. For contract research organizations, university laboratories, and pharmaceutical discovery teams, access to identity-verified peptide reference standards is a routine analytical necessity; sourcing gaps in this space have historically pushed researchers toward suppliers with inconsistent quality controls. The peptide and amino acid ingredient segment has seen growing demand for traceable, analytically characterized materials as institutional review boards raise documentation requirements.
The broader peptide research market is navigating a complicated regulatory environment. FDA has signaled that several peptides — including BPC-157, TB-500, and Selank — are not lawfully marketed as dietary supplements and has issued warning letters to finished-product sellers. The supplement regulation landscape has consequently pushed serious research-focused suppliers toward strict research-use-only labeling to maintain compliance and institutional credibility. Koi Peptides' move reflects that market bifurcation: a professional-tier, documentation-heavy channel for laboratory procurement versus consumer-facing supplement SKUs that continue to face enforcement risk.
For operators in the nutraceutical and functional food space, the practical takeaway is a cautionary one: BPC-157 remains outside the permissible finished-formulation pathway until human clinical data, GRAS affirmation, or an accepted NDI notification changes the regulatory calculus. Ingredient buyers and formulators should treat any supplier offering BPC-157 in a consumer-ready finished formulation as presenting significant compliance exposure. Koi Peptides' COA-verified research compound is intended to support the upstream science that may, eventually, build that evidentiary foundation — not to shortcut it.
Functional News is part of the Food & Beverage Magazine network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.